The drug discovery startup LabGenius, situated in London, UK, has secured £35 million in Series B investment.
Investors
- Merck’s corporate venture capital arm for strategy
- M Ventures
- Octopus Ventures
- LG Corp
- Atomico
- Kindred Capital
- Lux Capital
- Obvious Ventures
- LabGenius has received £58 million in capital overall.
Use of funds
The company plans to use the money to advance a wholly-owned pipeline of multispecific antibodies for the treatment of solid tumors toward the clinic and to further develop its exclusive machine learning (ML)-driven drug discovery platform, which facilitates the quick identification of biotherapeutics.
About LabGenius
LabGenius, a drug discovery firm that is leading the way in the identification of therapeutic antibodies of the next generation, is led by CEO Dr. James Field. Its EVATM discovery platform combines robotic automation, synthetic biology, and artificial intelligence technology. The firm has a hybrid business strategy, seeking a wholly-owned treatment pipeline in tandem with partnerships with major biotech and pharmaceutical companies.
The company’s new Board of Directors is composed of Oliver Hardick of M Ventures, Oliver Sims of Octopus Ventures, Irina Haivas of Atomico, Leila Zegna of Kindred Capital, James Field, the CEO, and Edwin Moses, the Independent Chair.
